Sparta Doublet Regimen for HCV
• Plan to initiate in the first half of 2015 a clinical trial with ACH-3422 in combination with ACH-3102 for patients with treatment-naïve genotype 1 HCV for treatment durations of 6, 8 and 12 weeks. SVR4 results are expected in the second half of 2015.
ACH-3422 Phase 1 Proof-of-concept for HCV Genotypes 2 and 3
• Plan to initiate during the first quarter a Phase 1 proof-of-concept trial evaluating the anti-viral activity of ACH-3422 for HCV genotypes 2 and 3. Results are anticipated during the second quarter of 2015.
Ithaca Triplet Regimen for HCV
• Expect to initiate during the first half of 2015 a proxy triplet trial evaluating ACH-3102 and sovaprevir with sofosbuvir for a treatment duration of 4 weeks. SVR4 results are expected in the second half of 2015; and
• Expect to initiate by the end of 2015 a pharmacokinetic and viral kinetic study of ACH-3422, ACH-3102 and sovaprevir in patients with treatment-naïve genotype 1 HCV.

你好百合，一直关注你的帖子。想问一下吃欧盟组合需要停保肝护肝的药吗？

听说有医院要试行美国的口服药，本来是15年开始到现在也没动静，你可以问问

说印度已经开始出仿制的药了 咱们再等等 会有好结果的

Hyderabad, Mar 12: Hetero, a Hyderabad-based pharmaceutical today announced that it has received approval for generic Sofosbuvir Tablets, 400 mg, from the Drug Controller General of India.
Hetero will launch Sofosbuvir under its brand Sofovir in India. It will price the generic medicine at Rs. 19,900/- for a bottle of 28 tablets and will launch the medicine this month in India and other countries soon.
The Pharma major has also tied up with various other Licensee holders to distribute the generic Sofosbuvir in India.
Sofosbuvir 400 mg tablets, a once-daily oral dose are being used for the treatment of chronic hepatitis C infection across the world. This is expected to usher in the beginning of a new era in Hepatitis-C treatment.
Hetero has a non-exclusive License Agreement with Gilead Sciences, Ireland to manufacture and sell generic versions of its chronic hepatitis C medicines in 91 developing countries.
"Hepatitis C is a growing public health concern, particularly in devel

:北京地坛医院，Cheng Jun
北京大学人民医院，魏来
北京右安医院，段钟平
北京友谊医院，贾继东
北京大学第一医院，王贵强
请验证。

感谢您的发帖，祝早日康复！

新 药 治 愈 标 准
相信我们真正治愈了一罗辛特K•特利用当前的治疗方案，慢性丙肝的治愈率高达90％。当被告之病毒检测不到时，每一个病人都会兴奋不已。然后，病人要用很久才能相信自己真正治愈了。
丙肝治疗获得成功的医学述语是SVR一sustained viral response ，在治疗完成后保持TND24周就是SVR24，最近，许多研究文献中用SVR12表示治疗获得成功。对于我们很难相信治疗结束后TND保持24周就是治愈了，那么，TND12周更是难以置信了。对于文献中的说法，我们能相信吗?
根据肝病专家埃略克•吉田和他的团队的研究报告，上面问题的答案对病人中的大多数来说是肯定的。研究报告说：利用索非布韦组合治疗后病人的SVR12与SVR24没有什么差别，即使组合中采用了干扰素。
为了分析使用索非布韦的研究数据，研究人员观察了基因1型到6型的应答率，其中，基因1，4，5，6型总共327个病人，基因2型294个，基因3型250个病人。（研究结果：在讲结果之前，先解释二个述语：1，复发relapse ，2，检测下限定量LLOQ）
研究结果:在获得SVR12的779个病人中有777个获得SVR24，其中2人没有获得SVR24的全是3型病人(无肝硬化，经治）如果不考虑3型，100％获得SVR12的病人都获得了SVR24。SVR4的情况如何呢?SVR4就不像SVR12一样可靠了。大多数复发都在4周内(66个复发，占复发人数的77•6％)，在4周到12周期间有17人复发，占复发人数的20％。
上海虹新老师根据原文翻译2015年2月23日

截止今天、印度、埃及产的上市的索菲布韦已经可以购买到，我知道靠谱的有三家代沟，具体代购渠道不方便发，大家可以各显神通了。

http://www.eda.mohealth.gov.eg/SearchRegDrugsRes.aspx?s=Mpiviropack&sType=1

下月据说老挝的欧盟组合也要上市。

印度药出现两个版本，有红色印度字的是natco印度上市的包装，纯英文是出口到尼泊尔的包装